According to Zhitong Finance APP, before the U.S. market open on November 6, Moderna (MRNA.US) reported its third-quarter 2026 results. The financial report showed that the company's total revenue was $1.313 billion, representing a year-over-year increase of
29%, significantly higher than the market expectation of approximately $885 million; net profit of $162 million, turning around from a net loss of $200 million in the same period last year; diluted earnings per share of $0.38
Dollar, significantly better than the market-expected loss of $1.25 per share
USD.
The company stated that revenue growth was primarily driven by strong international sales of the COVID-19 vaccine and the delivery of long-term strategic government contracts in the UK, Canada, Australia, and other markets. Revenue in the U.S. market for the quarter was $780 million, and international revenue was
$533 million.
Profitability improved in tandem: cost of sales amounted to $318 million (a 54% year-over-year increase, including $65 million in third-party royalties); research and development expenses were $583 million, decreasing year-over-year.
27%, primarily due to the completion of late-stage clinical trials for certain infectious disease pipelines and organizational cost optimization and efficiency improvements; operating profit of $130 million, compared to an operating loss of $260 million in the same period last year.
As of the end of September, cash and investments amounted to 80.
USD billion, up sequentially, primarily due to net proceeds of USD 2.6 billion from convertible bond issuance, partially offset by USD 950 million in litigation settlement expenses and seasonal working capital outflows.
The company raised its full-year guidance, significantly increasing the projected revenue growth rate for 2026 from "up to 10%" to 15%–25%, with expected revenue split approximately evenly between the U.S. and international markets; R&D expense guidance was revised from approximately $29
Reduced from $3 billion to approximately $2.7 billion; year-end cash and investments guidance increased from $4.7 billion to $5.2 billion to $8.1 billion to $8.3 billion.
Regarding business and pipeline, CEO Stéphane Bancel stated that the company has received approval for five products: the seasonal influenza vaccine mFLUSIVA was approved by the U.S. FDA in August (for use in individuals aged 50–64).
Aged 65 and older received accelerated approval; also approved in Canada; the flu/COVID-19 combination vaccine mCOFLU has been approved in Canada (EU brand)
mCOMBRIAX) is still under review in Japan, the United Kingdom, Australia, and other regions.
In the oncology pipeline, the personalized cancer vaccine intismeran, developed in collaboration with Merck Sharp & Dohme.
Positive Phase III results achieved for melanoma (data show that combination with Keytruda reduces the risk of recurrence or death by 42%). However, for the norovirus vaccine mRNA-1403
The interim analysis for Phase III did not meet the early success criteria, so the company will not add new study cohorts this quarter.
Moderna's stock has recently rebounded from a 52-week low of $22.28 to above $220, driven by melanoma data.